Niagen Bioscience, Inc. current report, 08 December 2023

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation (CDXC) on December 13, 2023, reporting events occurring on December 8, 2023. The filing details an amendment to the Company's existing business financing agreement with Western Alliance Bank.

Key Financial Metrics and Debt

  • Credit Facility: Revolving credit line of up to $10.0 million.
  • Outstanding Balance: $0 as of the filing date.
  • Interest Rate: Increased to a floating rate equal to the greater of 8.25% per year or the Prime Rate, plus 1.00%. An additional 5.00% applies during any event of default.
  • Maturity Date: Extended to November 12, 2025.

Material Changes Versus Prior Period

The amendment significantly altered the terms of the Credit Agreement compared to the prior period:

  • Interest Rate Increase: The base interest rate floor was raised from 3.25% to 8.25% per year.
  • Term Extension: The maturity date was extended from December 12, 2023, to November 12, 2025.
  • Covenant Adjustments: Financial covenants were revised regarding cash maintenance at the lender, the calculation methodology for the quick ratio, and minimum liquidity requirements.

Guidance, Outlook, and Risks

The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future performance. The primary risk disclosed is the increased cost of capital due to the higher interest rate floor. The filing notes that the summary of terms is qualified by the full text of the Amendment filed as Exhibit 10.2.

Investor Verification Checklist

  • Verify the current cash balance and liquidity position to ensure compliance with the revised minimum liquidity requirements.
  • Review the full text of Exhibit 10.2 to understand the specific changes to the quick ratio calculation.
  • Confirm the Company's ability to service the debt at the new interest rate floor of 8.25% should the facility be drawn.
  • Check for any subsequent filings regarding the utilization of the $10.0 million credit line.